DirectMeds Review: $297 Semaglutide With No Prepay Tier

$297 a month for compounded semaglutide by injection, $399 for compounded tirzepatide, and $249 for sublingual semaglutide. Those are the walk-away numbers as well as the headline ones, which is unusual: the storefront shows a single option per product, marked "0% off", with the sentence "$297.00 billed every month" printed underneath. Shipping is free, there’s no membership, and the Terms state the charge already includes pharmacy, medical-group and platform fees. Twelve months comes to $3,564, $4,788 and $2,988 respectively, before sales tax. Read on August 9, 2026 off directmeds.com/portal/products.

DirectMeds says there is one, and its storefront doesn’t show it. The FAQ on its product pages reads "We also offer new customer discounts, bulk pricing for 6- or 12-month plans", but every GLP-1 option in the portal shows at 0% off with no alternative tier beside it. The only percentage discounts anywhere in the storefront — 26% and 51% — belong to SatiaLean, a satiety supplement, not to a GLP-1. If a bulk price exists it’s quoted somewhere a shopper can’t see before buying, and on the evidence of the live checkout the monthly rate is the only rate.

Because it’s the wrong number. Every per-day badge on this site is the monthly price divided by 31 — $297 gives $9.58, $249 gives $8.03, the SatiaLean supplement at $119 gives $3.87. The marketing page for tirzepatide prints $399 a month beside $9.58 a day, which is semaglutide's figure; $399 ÷ 31 is $12.87. The checkout gets it right and shows $12.87. So the two DirectMeds pages for the same product disagree by about a third on what it costs per day, and the cheaper of the two is the one a search engine sends you to. The monthly price, $399, is consistent across both.

Canceling the subscription is easy; canceling an order isn’t. There are no contracts and no notice period to stop future shipments — you turn off auto-refill in the portal, or email or call, though the Terms ask for that at least 48 hours before the next processing date. An individual order is different: "You may attempt to cancel a prescription order within 24 hours of placing it (if not yet received by the provider network). After 24 hours, prescription orders generally cannot be canceled," and there are no refunds for medication already received. The one genuinely good term is at the front: if a provider declines to prescribe, DirectMeds says you get a full refund.

DirectMeds tells you, which most of this category doesn’t. Prescriptions for 42 states and Washington, D.C. are filled by CraftedRx at 609 N State Hwy 47, Suite C, Warrenton, Missouri; Alabama, California, Connecticut, North Carolina, South Carolina and Washington are filled by ChemistryRx at 950 Henderson Blvd, Folcroft, Pennsylvania. Both are named with addresses and phone numbers. That transparency is worth something — the private-label finding running through this enforcement wave, where a seller's own name on the vial implies it did the compounding, is absent from DirectMeds' letter. The one thing to discount is the phrase "our FDA pharmacy", which appears in its FAQ: FDA neither approves nor licenses compounding pharmacies, and no such designation exists.

Everywhere except Mississippi and Louisiana. DirectMeds publishes this as a sentence — "Direct Meds currently provides services to all US States EXCEPT Mississippi and Louisiana where prescription of weight loss medications via telehealth is prohibited" — and then, separately, as a list mapping every served jurisdiction to the pharmacy that fills it. The two lists add up to 48 states plus Washington, D.C., which reconciles exactly against the two exclusions. That’s a stronger form of disclosure than a count, and it’s checkable, which is why it’s repeated here rather than summarized.

On September 9, 2025 FDA wrote to directmeds.com, Inc. about language on directmeds.com that it had reviewed that August. It quoted three passages, among them "Compounded semaglutide contains the same active ingredient as branded semaglutide", and objected that "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not." That’s a misbranding finding under FDCA 502(a) and 502(bb) — about advertising, not about the drug. Nothing in it concerns sterility, potency or contamination, and there’s no private-label allegation of the sort several other letters in this wave carry. FDA's index shows no close-out letter. What is harder to explain is that the compounded tirzepatide and sublingual semaglutide pages now list "FDA approved for long term weight loss" outright, which claims more than the language FDA objected to.

It sits in the middle, and it stays there. $297 for compounded semaglutide is more than the cheapest advertised numbers you will see elsewhere, but those are almost always three-, six- or twelve-month blocks charged upfront and non-refundable, and the same sellers charge $299 or more if you buy a single month. DirectMeds' $297 is the single-month price, so it’s the number you can actually compare. The same holds at $399 for tirzepatide. Where it looks expensive is against its own sublingual product at $249, and where it looks cheap is against any seller that adds a membership on top of the medication line.